This Valentine’s Day, our client Boustead Securities, LLC, acting as the sole underwriter, completed the initial public offering (the “Offering”) of Soliton, Inc. (the "Company")  a pre-revenue stage medical device company with a proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center. The Company raised approximately $10.4 million in gross proceeds from this initial closing, before deducting underwriting commissions and other offering expenses, by issuing 2,086,391 ordinary shares at a public offering price of $5.00 per share. Soliton has been approved to begin trading its shares on the Nasdaq Capital Market under the symbol ”SOLY” on Tuesday February 19, 2019.  The Offering is the first IPO using Tier II of Regulation A to be completed on Nasdaq or NYSE in over one year.

In light of the federal government shutdown commencing on December 22, 2018, the U.S. Securities and Exchange Commission (“SEC”) remains leanly staffed. This has caused delay in staff’s review of registration statements and other filings, and the SEC will not be able to declare any registration statements effective during the shutdown. Nevertheless, regardless of the SEC’s operational status, EDGAR will still accept filings.